Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for HOOKIPA Pharma Inc. (HOOK : NSDQ)

• Company Description    HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body's immune system. HOOKIPA Pharma Inc. is based in New York, United States. Number of Employees: 157

• Price / Volume Information    Yesterday's Closing Price: $1.40 Daily Weekly Monthly 20 Day Moving Average: 383,139 shares Shares Outstanding: 54.69 (millions) Market Capitalization: $76.56 (millions) Beta: 1.07 52 Week High: $20.00 52 Week Low: $1.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.17% -8.14% 12 Week -43.55% -38.75% Year To Date -39.91% -28.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 350 FIFTH AVENUE 72ND FLOOR SUITE 7240 - NEW YORK,NY 10118 USA ph: 431-890-6360 fax: 43-1890-636-0399 ir@hookipapharma.com http://www.hookipapharma.com

• General Corporate Information    Officers Joern Aldag - Chief Executive Officer Jan van de Winkel - Chairman Reinhard Kandera - Chief Financial Officer Michael A. Kelly - Director David Kaufman - Director Peer Information HOOKIPA Pharma Inc. (CORR.) HOOKIPA Pharma Inc. (RSPI) HOOKIPA Pharma Inc. (CGXP) HOOKIPA Pharma Inc. (BGEN) HOOKIPA Pharma Inc. (GTBP) HOOKIPA Pharma Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 43906K100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 54.69 Most Recent Split Date: (:1) Beta: 1.07 Market Capitalization: $76.56 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 12.94% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.49 Price/Cash Flow: - Price / Sales: 5.25 EPS Growth vs. Year Ago Period: 24.53% vs. Previous Quarter: 38.46% Sales Growth vs. Year Ago Period: -72.74% vs. Previous Quarter: -62.90% ROE 03/31/22 - -70.82 12/31/21 - -65.28 09/30/21 - -50.48 ROA 03/31/22 - -52.76 12/31/21 - -50.08 09/30/21 - -40.18 Current Ratio 03/31/22 - - 12/31/21 - 3.69 09/30/21 - 4.45 Quick Ratio 03/31/22 - - 12/31/21 - 3.69 09/30/21 - 4.45 Operating Margin 03/31/22 - -523.54 12/31/21 - -410.15 09/30/21 - -339.35 Net Margin 03/31/22 - -523.54 12/31/21 - -410.15 09/30/21 - -339.35 Pre-Tax Margin 03/31/22 - - 12/31/21 - -410.15 09/30/21 - -339.34 Book Value 03/31/22 - - 12/31/21 - 2.87 09/30/21 - 4.15 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.02 09/30/21 - 0.02 Debt-to-Capital 03/31/22 - - 12/31/21 - 2.42 09/30/21 - 1.97

Powered by Zacks Investment Research ©